August 2000
Worldwide Biotech;Aug2000, Vol. 12 Issue 8, p1
Trade Publication
Announces the results of British Biotech's Phase III clinical trial of the oral matrix metalloproteinase inhibitor, marismat.


Related Articles

  • British Biotech's MMPIs flop yet again. Bouchie, Aaron // Nature Biotechnology;Apr2001, Vol. 19 Issue 4, p297 

    Reports on clinical failures of two matrix metalloproteinase inhibitors as cancer treatments of Oxford, Great Britain-based British Biotech PLC. Other marimastat trials under a sixty million dollar deal with Kenilworth, New Jersey-based Schering-Plough.

  • Corporate punishment. Gopal, Kevin // Pharmaceutical Executive;Apr98, Vol. 18 Issue 4, p36 

    Reports that British Biotech PLC has suspended its head of research pending an inquiry into alleged misconduct. Impact of the suspension on the company's financial performance; Optimism of the company on the successful development of marimastat for cancer.

  • BRITISH BIOTECH PLC REPORTS DECREASE IN LOSS FOR 1999.  // Biotech Financial Reports;Aug99, p4 

    Presents the 1999 financial statement of British Biotech PLC in Oxford, England. Statistics on net loss; Impact of the decrease in net loss on income and levels of expenditure of the company; Account on total amount of turnover and company cash utilization; Review of the various products of the...

  • The gene genie. Kenward, Michael // Director;Oct97, Vol. 51 Issue 3, p105 

    Profiles Keith McCullagh, chief executive of British Biotechnology pharmaceutical company based in Great Britain. Comments from McCullagh on the company; What made McCullagh and co-owner, Brian Richards established the company; Information on the company.

  • `I'll show them!' Kover, Amy // Fortune;6/22/1998, Vol. 137 Issue 12, p185 

    Looks at the stock of British Biotech (BBIOY), as of June 1998. The decline in the stock's price following negative statements made by David Millar, head of research at BBIOY, about the company's clinical practices; Graph showing the stock prices of BBIOY from 1996 to 1998.

  • Rights issue take-up for British Biotech `disappointing.' Page, Ginny // Nature;7/25/1996, Vol. 382 Issue 6589, p289 

    Informs that biotechnology company British Biotech met with mixed reactions to its share offering in July 1996. Only 49 percent of shareholders taking up their right to buy additional shares; The largest single fundraising effort by a British biotechnology firm; The company's focus on the...

  • Cancer pill on trial. Coghlan, Andy // New Scientist;5/20/95, Vol. 146 Issue 1978, p20 

    Reports that trials for an anti-tumor drug have begun in the United States and Great Britain. Development of the drug BB-2516 by British Biotech; Stabilization of tumors by the drug; Neutralization of enzymes overproduced by tumors; Safety tests on the drug; Doses given to cancer patients.

  • Secrets & lies. Gopal, Kevin // Pharmaceutical Executive;May98, Vol. 18 Issue 5, p32 

    Reports on an accusation of withholding adverse information against British Biotech. Drop in the company's market capitalization; Explanation on the company's decision not to tell investors immediately; Departure of Doctor Andrew Millar, head of the company's clinical research.

  • British Biotech redefines itself. Davidson, Sylvia // Nature Biotechnology;Aug2000, Vol. 18 Issue 8, p821 

    Focuses on the success of Oxford, England-based British Biotech PLC in reducing its annual losses. Amount of the loses saved by the company; Products produced by the company; Future plans of the company.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics